Background: The polycomb group protein enhancer of zeste homologue 2 (EZH 2) has been reported as a marker of aggressive breast cancer. The aim of this study was to investigate the correlation between the expression of EZH 2 with p53 and Ki-67 expression and other clinicopathological parameters in primary breast carcinomas in order to determine the role of the above marker as a prognosticator of tumor aggressiveness and patient outcome. Patients and Methods: One hundred primary operable breast cancer patients were investigated in order to identify the expression of EZH 2, Ki-67 and p53 in imprint smears immunocytochemically. The prevalence of expression of these markers was then correlated with clinicopathological parameters. Follow-up was available for all patients. Results: EZH 2 was expressed in 64% of the cases and correlated with higher levels of p53 (relative risk = 3.00, p < 0.0001) and Ki-67 (relative risk = 3.25, p < 0.0001). Malignant cells showed immunoreactivity for all markers in the nucleus. Univariate analysis revealed a strong association between EZH 2 protein expression and tumor grade and size, lymph node metastasis, and HER-2 and estrogen and progesterone receptor status. Multivariable statistical analysis revealed that lymph node metastasis was the main predictor for EZH 2 expression. Decreased patient survival was also significantly associated with EZH 2 expression (p < 0.0001). Conclusions: EZH 2 expression may be a marker of poor prognosis in breast carcinoma patients and has been suggested as a candidate for targeted therapy.

Keywords:
Breast carcinoma, EZH 2, Ki-67, p53
1.
Daidone MG, Povradiso A, Gion M, Harbeck N, Sweep F, Schmitt M: Biomolecular features of clinical relevance in breast cancer. Eur J Nucl Med Mol Imaging 2004;31(suppl 1):S13–S14.
2.
Mitra AP, Lin H, Cote RJ, Datar RH: Biomarker profiling for cancer diagnosis, prognosis and therapeutic management. Natl Med J India 2005;18:304–312.
3.
Krajewski S, Krajewska M, Turner BC, Pratt C, Howard B, Zapata JM, Frenkel V, Robertson S, Ionov Y, Yamamoto H, Povrucho M, Takayama S, Reed JC: Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 1999;6:29–40.
4.
Madjd Z, Mehrjerdi AZ, Sharifi AM, Molanaei S, Shahzadi SZ, Asadi-Lari M: CD44+ cancer cells express higher levels of the antiapoptotic protein Bcl-2 in breast tumors. Cancer Immun 2009;9:4.
5.
Tan PH, Bay BH, Yip G, Selvovrajan S, Tan P, Wu J, Lee CH, Li KB: Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 2005;18:374–381.
6.
Daidone MG, Luisi A, Veneroni S, Benini E, Silvestrini R: Clinical studies of Bcl 2 and treatment benefit in breast cancer patients. Endocr Relat Cancer 1999;6:61–68.
7.
Dalquen P, Baschiera B, Chaffard R, Dietrich H, Feichter GE, Kremer K, Torhosst J: MIB-1(Ki-67) immunostaining of breast cancer cells in cytologic smears. Acta Cytol 1997;41:229–237.
8.
Itaya M, Yoshimoto J, Kojima K, Kawasaki S: Immunohistochemistry of p53, Bcl-2 and Ki-67 as predictors of chemosensitivity. Methods Mol Med 2005;110:213–227.
9.
Sherr CJ, McCormick F: The RB and p53 pathways in cancer. Cancer Cell 2002;2:103–112.
10.
Zeidler M, Kleer C: The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer. J Mol Histol 2006;37:219–223.
11.
Tonini T, D’andrilli G, Fucito A, Gaspah L, Bagella L: Importance of EZH 2 polycomp protein in tumorigenesis process interfering with the pathway of growth suppressive key elements. J Cell Physiol 2008;214:295–300.
12.
Ding L, Kleer C: Enhancer of Zeste 2 as a marker of preneoplastic progression in the breast. Cancer Res 2006;66:9352–9355.
13.
Wei Y, Xia W, Zhang Z, Liu J, Wanh H, Adsay N, Abbarracin C, Yu D, Abbruzzese J, Mills G, Bast R, Hortobagyu G, Hung MC: Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 2008;47:701–706.
14.
Simon JA, Lange CA: Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008;647:21–29.
15.
Koss LG, Melamed R (eds): Koss’ Diagnostic Cytology and Its Histopathologic Bases, ed 5. Philadelphia, Lippincott Williams &amp; Wilkins, 2005, vol 2, pp 1592–1593, 1615–1616.
16.
Tavassoli F, Devilee P (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, IARC Press, 2003, p 10.
17.
Page DL, Anderson TJ: Diagnostic Histopathology of the Breast. Edinburgh, Churchill Livingstone, 1987, pp 303–307.
18.
Cytology Subgroup of the National Coordinating Committee for Breast Cancer Screening Pathology: Guidelines for cytology procedures and reporting on fine needle aspirates of the breast. Cytopathology 1994;5:316–334.
19.
Bast RC, Raudin P, Hayes DF, et al: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865–1878.
20.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007;608:1–22.
21.
Tsakonas G, Kosmas C: Integration of novel targeted therapies into the systemic treatment of breast cancer – a review. J BUON 2007;12:319–327.
22.
Cotter TG: Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009;9:501–507.
23.
Shen Y, White E: p53 dependent apoptosis pathways. Adv Cancer Res 2001;82:55–84.
24.
Wiesner F, Magener A, Fasching P, Wesse J, Bani M, Rauh C, Jud S, Schraceder M, Loehberg C, Beckmann M, Hartmann A, Lux M: Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast 2009;18:135–141.
25.
von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, Hilfrich J, Merkle E, Jackisch C, Costa S, Caputo A, Kaufmann M, German Breast Group: Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res 2008;10:R30.
26.
Jacquemier J, Charafe-Jauffret E, Monville F, Esterni B, Extra J, Houvenaeghel G, Xerri L, Bertucci F, Birnbaum D: Association of GATA3, p53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Breast Cancer Res 2009;11:R23.
27.
Collett K, Eide G, Ames H, Stefansson I, Eide J, Brocaten A, Aas T, Otte A, Akslen L: Expression of Enhancer of Zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006;12:1168–1175.
28.
Mattiou E, Vogiatzi P, Sun A, Abbadessa G, Angeloni G, D’ugo D, Trani D, Gaughan J, Vecchio F, Cevenini G, Persiani R, Giordano A, Claudio P: Immunohistochemical analysis of pRb2/p130, VEGF, EZH 2, p53, p16INK4A, p27KIP1, p21WAF1, Ki-67 expression patterns in gastric cancer. J Cell Physiol 2007;210:183–191.
29.
Takeshita F, Minakuchi Y, Naghahara S, Honma K, Sasaki H, Hirai K, Teratani T, Namatame N, Yamamoto Y, Hanai K, Kato T, Sano A, Ochiya T: Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005;102:12177–12182.
30.
Machmann I, Haluorsen O, Collett K, Stefansson I, Straume O, Haukaas S, Salvesen H, Otte A, Akslen L: EZH 2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate and breast. J Clin Oncol 2006;24:268–273.
31.
Kleer C, Cao Q, Varambally S, Shen R, Ota I, Tomlins S, Ghosh D, Sewalt R, Otte A, Hayes D, Sabel M, Livant A, Weiss S, Rubin M, Chinnaiyan A: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003;100:11606–11611.
32.
Raaphorst FM, Meijer CJ, Fieret E, et al: Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH 2 gene. Neoplasia 2003;5:481–488.
33.
van’t Veer LJ, Dai H, van de Vijver M, He Y, Hart A, Mao M, Peterse H, van der Kooy K, Marton M, Witteveen A, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530–536.
34.
van der Vlag J, Otte A: Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet 1999;23:474–478.
35.
Beier R, Burgin A, Kiermaier A, et al: Induction of cyclin E-cdK2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events. EMBO J 2000;19:5813–5823.
36.
Bracken AP, Pasini D, Capra M, et al: EZH 2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323–5335.
37.
Tang X, Milyavsky M, Shats I, et al: Activated p53 suppresses the histone methyltransferase EZH 2 gene. Oncogene 2004;23:5759–5769.
38.
Norberg T, Klaar S, Kourf G, et al: Increased p53 mutation frequency during tumor progression-results from a breast cancer cohort. Cancer Res 2001;61:8317–8321.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.